Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 105 participants.
Also called NCT05365438
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 105 participants
- Registry
-
NCT05365438
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT05365438. Randomized; single masking; primary purpose treatment. Start 2022-10-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
- Condition
- Dyslipidemias
- Condition
- Atherosclerosis
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Omega 3-Atorvastatin
- Intervention (Drug)
- Omega 3-Atorvastatin
- Intervention (Drug)
- Atorvastatin-Ezetimibe
- Lead sponsor
- Seoul National University Bundang Hospital
- Collaborator
- Korea United Pharm. Inc.
Record details
- Record id
cardio:ct-nct05365438- Content hash
0552d099ad76d64af92f16c81a210280a1ac627cd67e8240a8b6a645f6c15004